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Escherichia vulneris is a recently identified environmental
organism that can colonize humans and animals. It has mainly
been recovered from human wounds.1 Very few infections
with E. vulneris have been reported. Pien et al.2 described a
series of 12 Hawaiian patients who had E. vulneris isolated
from soft tissues. It now seems clear that these organisms can
cause invasive infections in immunocompetent and immuno-
depressed patients, as is shown in the following case.
A 70-year-old man, treated two years previously for
chronic lymphocytic leukemia and followed in the Depart-
ment of Hematology, was admitted to the hospital because of
rigors, fever and left gonalgia. He was allergic to beta-
lactams and received no medications as prophylaxis. On
physical examination, his temperature was 39 8C, and there
was a tenderness of the knee, where a subcutaneous mass
was detected with fluctuation. He had a blood pressure of
100/80 mmHg, and the remainder of the examination was
unremarkable. Laboratory examination revealed hemoglobin
of 12.7 g/l, a white blood cell count of 7.8  109/l, and a
platelet count of 335  109/l. Routine blood chemistry and
coagulation tests were normal, except for a C-reactive pro-
tein level of 191 mg/l. Blood cultures yielded Gram-negative
bacilli, identified as E. vulneris by Vitek 1 (bioMerieux).
Susceptibility testing was performed according to the NCCLS
disk diffusion method. The same organism was isolated in the
pus of a subcutaneous abscess after drainage. The organism
was susceptible to ampicillin, cephalosporins, aminoglyco-
sides (gentamicin, amikacin and streptomycin), quinolones
(ciprofloxacin, ofloxacin and levofloxacin) and cotrimoxa-
zole. Surgical debridement was not recommended. The
patient was treated with a combination of ciprofloxacinand gentamicin for one week, and then ciprofloxacin for
seven days. He was discharged on day 15 of treatment, with
almost complete resolution of the soft tissue infection; he
continued the ciprofloxacin treatment for a further 15 days.
At follow-up 2 weeks after completion of treatment, he was
well without any symptoms.
Since 1982, E. vulneris has been classified in the family of
Enterobacteriaceae in Enteric Group 1, on the basis of DNA
relatedness studies and biochemical reactions. It has been
isolated from animals, the environment, potable water and
humans,1,3 where it can colonize many sites, especially
wounds.2 Escherichia vulneris has been identified in many
invasive infections, including osteomyelitis,4 bacteremia,5
urosepsis,6 septic shock7 and meningitis.8 More recently, a
peritonitis in the setting of peritoneal dialysis has been
reported9 in an elderly female patient. Our patient presented
with a colonization of his wound causing a local sepsis, and
because of immunosuppression due to a lymphoproliferative
disorder, bacteremia occurred with the same agent. It is
unclear whether hematologic malignancies, such as myelo-
proliferative or lymphoproliferative disorders, play a role in
the pathogenesis of such infections.
In wounds with E. vulneris infection, co-infection with
other bacteria has been reported, and this may contribute to
the extensive tissue injury seen in such cases.7 Clinical
isolates of E. vulneris are slightly more susceptible to the
commonly used antibiotics than Escherichia coli or Escher-
ichia hermannii, especially aminoglycosides and ticarcillin.10
A reduction in the susceptibility of some strains may suggest a
nosocomial source of the disease.8
In conclusion, to our knowledge, this is the first reported
case of E. vulneris bacteremia in a patient with chronic
lymphocytic leukemia in Tunisia, demonstrating that the
organism is a true pathogen.
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doi:10.1016/j.ijid.2007.04.005Figure 1 Dissemination of visceral leishmaniasis to the skin.Gastric and cutaneous dissemination of visceral
leishmaniasis in a patient with advanced HIV
Visceral leishmaniasis (VL) is a well-recognized opportunistic
infection in patients with HIV-1 infection. Several reports
indicate a rising trend in VL/HIV co-infection. Themajority of
HIV/Leishmania co-infected cases show classic features of
VL. Atypical features such as dissemination to the gastro-
intestinal tract and to the skin may also occur.
We describe herein a patient with advanced HIV-1 infec-
tion residing in a non-endemic area for leishmaniasis. The
diagnosis of HIV had been made 4 years prior to this admis-
sion. Unfortunately, the Centers for Disease Control and
Prevention (CDC) stage at the time of diagnosis was not
known. He presented with atypical features of visceral
leishmaniasis. In particular, the patient had dissemination
to the esophagus, the stomach, and to the skin.
A 50-year-old Omani male presented with progressive
dysphagia, diarrhea with vague abdominal pain, severe anor-
exia, and weight loss of 20 kg over 6 months. A history of
intermittent episodes of high-grade fever, chills, night
sweats, weakness, and occasional headaches was elicited.
The patient had also noticed the appearance of multiple
pigmented plaques over his face and neck during the same
period. He had lost the vision in his left eye 3 months earlier.
The patient denied any history of travel outside Oman.
Examination showed a sick looking patient with severe
wasting and marked pallor. He was febrile and had neck
stiffness with intact sensorium and no focal deficit. Skin
examination revealed multiple pigmented plaques of 3 1 cm over the right mandible and left base of the neck
(Figure 1). Similar lesions were seen over the hard palate.
Multiple enlarged cervical lymph nodes were noted with no
hepatosplenomegaly. The patient had no light perception in
the left eye; visual acuity in the right eye was limited to
finger counting. Fundoscopy showed changes consistent with
cytomegalovirus (CMV) retinitis in both eyes.
Laboratory findings were as follows: full blood count
revealed anemia (Hb 9.6 g/dl), leukopenia (white blood cell
count: 2.97  109/l), and a normal platelet count (276 
109/l). ELISA and Western blot for HIV-1 was positive. The
HIV-1 viral load was 480 000 RNA copies/ml, with an absolute
CD4 count of 3.0/ml, CD4/CD8 ratio of 0.005:1.
